BR112013012783A2 - composições com rápida desintegração compreendendo nabilona e beta ciclodextrina aleatoriamente metilada e metodo de produção - Google Patents

composições com rápida desintegração compreendendo nabilona e beta ciclodextrina aleatoriamente metilada e metodo de produção

Info

Publication number
BR112013012783A2
BR112013012783A2 BR112013012783A BR112013012783A BR112013012783A2 BR 112013012783 A2 BR112013012783 A2 BR 112013012783A2 BR 112013012783 A BR112013012783 A BR 112013012783A BR 112013012783 A BR112013012783 A BR 112013012783A BR 112013012783 A2 BR112013012783 A2 BR 112013012783A2
Authority
BR
Brazil
Prior art keywords
nabilone
production method
randomly methylated
rapidly disintegrating
beta cyclodextrin
Prior art date
Application number
BR112013012783A
Other languages
English (en)
Inventor
Schueller Regina
Toegel Stefan
Viernstein Helmut
Original Assignee
Aop Orphan Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aop Orphan Pharmaceuticals Ag filed Critical Aop Orphan Pharmaceuticals Ag
Publication of BR112013012783A2 publication Critical patent/BR112013012783A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

composições com rápida desintegração compreendendo nabilona e beta ciclodextrina aleatoriamente metilada e metodo de produção. a presente invenção fornece uma nova composição compreendendo nabilona e <225>-ciclodextrina aleatoriamente metilada (rameb), em que a relaçãode peso (peso seco para peso em seco) entre nabilona e rameb é cerca de 1:60 - 1:140. a presente invençãon ainda fornece métodos para aumentar a biodisponibilidade da nabilona.
BR112013012783A 2010-11-25 2011-11-24 composições com rápida desintegração compreendendo nabilona e beta ciclodextrina aleatoriamente metilada e metodo de produção BR112013012783A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10192497 2010-11-25
PCT/EP2011/070951 WO2012069591A1 (en) 2010-11-25 2011-11-24 Fast disintegrating compositions comprising nabilone and randomly methylated beta cyclodextrin

Publications (1)

Publication Number Publication Date
BR112013012783A2 true BR112013012783A2 (pt) 2016-09-13

Family

ID=43709011

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013012783A BR112013012783A2 (pt) 2010-11-25 2011-11-24 composições com rápida desintegração compreendendo nabilona e beta ciclodextrina aleatoriamente metilada e metodo de produção

Country Status (16)

Country Link
US (1) US20130295026A1 (pt)
EP (1) EP2643022B1 (pt)
JP (1) JP2014501728A (pt)
AU (1) AU2011333683A1 (pt)
BR (1) BR112013012783A2 (pt)
CA (1) CA2817177A1 (pt)
EA (1) EA201300616A1 (pt)
ES (1) ES2687098T3 (pt)
IL (1) IL226316A (pt)
MX (1) MX2013005315A (pt)
NZ (1) NZ609356A (pt)
PL (1) PL2643022T3 (pt)
SG (1) SG190024A1 (pt)
TR (1) TR201815752T4 (pt)
WO (1) WO2012069591A1 (pt)
ZA (1) ZA201302703B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015119641A1 (en) * 2014-02-07 2015-08-13 Scilabs Pharmaceuticals All natural, non-toxic sublingual drug delivery systems
CA2845443A1 (en) * 2014-03-04 2015-09-04 Pharmascience Inc. Orally disintegrating tablet of nabilone and method of manufacturing
EP3445356B1 (en) 2016-04-22 2021-06-30 Receptor Holdings, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
WO2018058235A1 (en) * 2016-09-27 2018-04-05 CannTab Therapeutics Limited Sustained release cannabinoid formulations
CA3044880A1 (en) 2016-11-24 2018-05-31 Aop Orphan Pharmaceuticals Ag Cannabinoids for prophylactic treatment of involuntary weight loss
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
BR112019013743A2 (pt) * 2017-01-03 2020-01-21 Receptor Holdings Inc compostos medicinais e suplementos nutricionais
US10058531B1 (en) 2017-06-01 2018-08-28 Spartak LLC Dosage delivery film

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20020333A0 (fi) * 2002-02-20 2002-02-20 Tomi Jaervinen Metyloidun syklodekstriinin uudet kompleksit
US20040229939A1 (en) * 2003-02-14 2004-11-18 Chowdhury Dipak K. Tetrahydrocannabinol compositions and methods of manufacture and use thereof
US8735374B2 (en) * 2009-07-31 2014-05-27 Intelgenx Corp. Oral mucoadhesive dosage form

Also Published As

Publication number Publication date
ZA201302703B (en) 2014-06-25
PL2643022T3 (pl) 2018-12-31
IL226316A0 (en) 2013-07-31
TR201815752T4 (tr) 2018-11-21
EP2643022A1 (en) 2013-10-02
JP2014501728A (ja) 2014-01-23
EP2643022B1 (en) 2018-07-25
EA201300616A1 (ru) 2013-10-30
WO2012069591A1 (en) 2012-05-31
MX2013005315A (es) 2013-06-03
US20130295026A1 (en) 2013-11-07
CA2817177A1 (en) 2012-05-31
SG190024A1 (en) 2013-06-28
IL226316A (en) 2016-11-30
ES2687098T3 (es) 2018-10-23
AU2011333683A1 (en) 2013-05-09
NZ609356A (en) 2014-10-31

Similar Documents

Publication Publication Date Title
BR112013012783A2 (pt) composições com rápida desintegração compreendendo nabilona e beta ciclodextrina aleatoriamente metilada e metodo de produção
BR112013024953A2 (pt) processo para preparar as partículas de pigmento autoligantes, suspensão de partícula de pigmento autoligante, e, uso da suspensão de partícula de pigmento autoligante
CY1125061T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει δροσπιρενονη για χρηση ως ενα αντισυλληπτικο
BR112013020513A2 (pt) adoçante stevia altamente solúvel
BRPI0823506A8 (pt) composições e métodos para a produção de isoprene
CU20120122A7 (es) Derivados 5-aril-1,2,4-triazolona ligada a bisarilo sustituidos
BR112012028291A2 (pt) composições farmacêuticas e métodos para sua produção
BR112013003597A2 (pt) partículas umidificadas compreendendo uma substância terapeuticamente ativa
BR112016015496A2 (pt) composição e processo para a produção da composição
BR112012007085B8 (pt) processos para a preparação de derivados de benzil-benzeno substituídos com glicopiranosila
BR112012020857A2 (pt) substrato gerador de aerossol para artigos para fumar
BR112014017851A8 (pt) Composição de polímero que compreende nanotubos de carbono
BR112012011474A2 (pt) estruturas espaciais de compósito com cnt adaptado.
BRPI1003794A2 (pt) composição e produto de reação
ECSP10010434A (es) Inhibidores de hsp90
ECSP13012519A (es) Compuestos sustituidos de benzamida
BRPI1002587A2 (pt) composição e produto de reação
EA201070605A8 (ru) Применение бактерий для производства биоэнергии
BR112013028449A2 (pt) composições compreendendo partículas de hidrogel
BR112014014939A2 (pt) composição de tratamento de sementes
BR112012031508A2 (pt) composição e uso da mesma
BR112012033637A8 (pt) Macarrão seco e processo para produzir o mesmo
CO6410257A2 (es) Herbicidas novedosos
BR112013031307A2 (pt) métodos para tratamento de material lignocelulósico
CL2015001016A1 (es) Composiciones de ciclodextrinas alquiladas, y sus procesos para prepararlas y usar las mismas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 9/46 (2006.01), A61K 9/00 (2006.01), A61K 9/2

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2541 DE 17-09-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.